Sign in Subscribe
Antibodies

Improving COVID-19 Diagnosis with T-SPOT Assays

Strategic Insights

— 1 min read

Researchers at the University of Paris have made significant progress in diagnosing past COVID-19 infections using a combination of T-SPOT assays and antibody tests. The study aimed to evaluate the efficacy of T-SPOT assays in detecting cell-mediated immune responses against SARS-CoV-2. The findings suggest that integrating cellular and humoral immunity assays can facilitate COVID-19 prevalence studies.

Key Takeaways:

  • The study included 122 participants with PCR-confirmed COVID-19 and 67 participants with no evidence of prior infection.
  • The T-SPOT Discovery SARS-CoV-2 assays demonstrated comparable performance to antibody tests, with a sensitivity of 62.5% and specificity of 98.4% for the Tspot_N assay.
  • The combination of the Tspot_N test and the Lumi_N antibody test significantly improved the sensitivity and AUC to 88.0% and 0.979, respectively (p = 0.012).
  • Frozen PBMCs were found to be useful for performing T-SPOT assays.
  • The research concluded that integrating cellular and humoral immunity assays can facilitate COVID-19 prevalence studies.
  • The study was conducted by researchers from the University of Paris, including Michael T. White, Masaki Yamamoto, Takahisa Kawaguchi, Kazuya Setoh, Yusuke Tsuda, Koh Shinohara, Yasuhiro Tsuchido, Yasufumi Matsumura, Fumihiko Matsuda, and Miki Nagao.

Statistics:

  • Sensitivity of the Tspot_N assay: 62.5% (95% CI: 52.0%-72.2%)
  • Specificity of the Tspot_N assay: 98.4% (95% CI: 91.2%-100.0%)
  • Area under the receiver operating characteristic curve (AUC) for the Tspot_N assay: 0.923
  • Sensitivity of the combination assay (Tspot_N and Lumi_N): 88.0%
  • AUC for the combination assay: 0.979

Sources:

  • NewsRx. Studies from University of Paris in the Area of COVID-19 Reported (Improving the diagnostic performance for prior COVID-19 with T-SPOT, an interferon-gamma release assay). Medical Letter on the CDC & FDA. October 26, 2025; p 239.
  • Improving the diagnostic performance for prior COVID-19 with T-SPOT, an interferon-gamma release assay. Frontiers in Microbiology, 2025;16:1675605. Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.

Read more